Pregnancy

Clarivate Companies to Watch Report Spotlights Seven Women’s Health Startups Shaping the Future of Care

Report highlights emerging biotech innovators advancing new therapies, equity and investment across reproductive, chronic and mental health LONDON, Nov. 13,...

Carrot Partners with ŌURA and Dexcom to Deliver Deeper Insights and Experiences for Members on Fertility, Family-Building, and Hormonal Health Journeys

Wearable technology integration, including CGM, supports Carrot's Sprints program participants with expert clinical insights WEST DES MOINES, Iowa, Nov. 12,...

Desert Oasis Healthcare Expands Maternal Health Resources with New Maternal Health Educator Position and Updated Video Education Series

DOHC strengthens its commitment to mothers and families through expanded education and personalized prenatal support PALM SPRINGS, CALIFORNIA / ACCESS...

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in...

error: Content is protected !!